⌘K
Loading ticker…
As of 2026-08-24, Vertex Pharmaceuticals Inc (VRTX) has a 3-month relative strength percentile of 85 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 58. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.8%, relative volume 0.57×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
VRTX is in a stage 2 uptrend, week 6. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 11.1% / 18.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
VRTX is held by 111 ETFs as of May 2026. Top owner: QQQM at 0.50% weight, $483M notional. Top 3 carry $1.2B.
Held by 347 ETFs · $21.9B across latest filings · largest weight 8.22% (TBXU).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| QQQMInvesco NASDAQ 100 ETF | 0.50% | $483M | −0.18 pp |
| CGGR | 1.56% | $379M | −0.33 pp |
| VHTVanguard Health Care ETF | 1.80% | $341M | −0.09 pp |
| CGDVCapital Group Dividend Value ETF | 0.80% | $282M | −0.64 pp |
| SCHGSchwab U.S. Large-Cap Growth ETF |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.40% |
| $243M |
| −0.08 pp |
| VONGVanguard Russell 1000 Growth ETF | 0.34% | $188M | −0.10 pp |
| CGUS | 1.58% | $171M | −0.31 pp |
| CGGO | 1.14% | $129M | −0.20 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.17% | $121M | −0.04 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.16% | $67M | −0.03 pp |
Showing 10 of 111 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VRTX Jan avg: 9.17% median: 9.20% win: 100% σ: 5.00% n: 4 2022-04-12 → 2026-07-31 | VRTX Feb avg: -0.85% median: 0.50% win: 50% σ: 7.23% n: 4 2022-04-12 → 2026-07-31 | VRTX Mar avg: -0.30% median: 0.20% win: 50% σ: 7.67% n: 4 2022-04-12 → 2026-07-31 | VRTX Apr avg: 0.02% median: -2.80% win: 40% σ: 6.22% n: 5 2022-04-12 → 2026-07-31 | VRTX May avg: 0.14% median: -1.67% win: 40% σ: 10.94% n: 5 2022-04-12 → 2026-07-31 | VRTX Jun avg: 5.66% median: 4.89% win: 100% σ: 4.20% n: 5 2022-04-12 → 2026-07-31 | VRTX Jul avg: 0.81% median: 0.12% win: 60% σ: 3.63% n: 5 2022-04-12 → 2026-07-31 | VRTX Aug avg: -3.76% median: -0.55% win: 50% σ: 7.14% n: 4 2022-04-12 → 2026-07-31 (current) | VRTX Sep avg: -0.87% median: -0.01% win: 50% σ: 3.80% n: 4 2022-04-12 → 2026-07-31 | VRTX Oct avg: 5.72% median: 5.95% win: 100% σ: 2.99% n: 4 2022-04-12 → 2026-07-31 | VRTX Nov avg: -0.09% median: -0.12% win: 50% σ: 2.03% n: 4 2022-04-12 → 2026-07-31 | VRTX Dec avg: -0.87% median: -2.09% win: 50% σ: 12.97% n: 4 2022-04-12 → 2026-07-31 |